Treatments in Endocrinology

, Volume 5, Issue 4, pp 223–228 | Cite as

Somatropin Therapy for Children with Prader- Willi Syndrome

Guidelines for Use
Therapy In Practice

Abstract

Prader-Willi syndrome is a neurogenetic disorder that occurs due to the lack of a paternally expressed gene or genes on chromosome 15qll-ql3. Many of the symptoms present in Prader-Willi syndrome are due to a hypothalamic-pituitary dysfunction. The main characteristics are muscular hypotonia, delayed psychomotor development, insatiable appetite resulting in overweight if a diet is not maintained, compromised growth and puberty resulting in a short final height and incomplete sexual development, respiratory disturbances, and dysmorphic features. Individuals with Prader-Willi syndrome have compromised growth and abnormal body composition with increased fat mass, decreased lean body mass, and low bone density, resembling a growth hormone-deficient status. Somatropin treatment has a beneficial effect on growth with increased final height and an improvement in and maintenance of body composition, as well as a beneficial effect on respiratory functions. Before initiating somatropin therapy, weight should be kept at an appropriate level, and polysomnography, as well as an otorhinolaryngologic examination should be performed. During somatropin therapy, carbohydrate metabolism and the development of scoliosis should be monitored, as well as bodyweight.

A comprehensive team to manage the various components of medical, psychologic, and sociologic care is required for individuals with Prader-Willi syndrome.

Keywords

Lean Body Mass Final Height Peak Growth Hormone Muscular Hypotonia Abnormal Body Composition 

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Holm VA, Cassidy SB, Butler MG, et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993; 91: 398–402PubMedGoogle Scholar
  2. 2.
    Gunay-Aygun M, Schawartz S, Heeger S, et al. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001; 108(5): e92PubMedCrossRefGoogle Scholar
  3. 3.
    Wharton RH, Loechner KJ. Genetic and clinical advances in Prader-Willi syndrome. Curr Opin Pediatr 1996; 8: 618–24PubMedCrossRefGoogle Scholar
  4. 4.
    Cassidy SB. Prader-Willi syndrome. J Med Genet 1997; 34: 917–23PubMedCrossRefGoogle Scholar
  5. 5.
    Nicholls RD, Ohta T, Gray TA. Genetic abnormalities in Prader-Willi syndrome and lessons from mouse models. Acta Paediatr Suppl 1999; 88: 99–104PubMedCrossRefGoogle Scholar
  6. 6.
    MacDonald HR, Wevrick R. The Necdin gene is deleted in Prader-Willi syndrome and is imprinted in human and mouse. Hum Mol Genet 1997; 6: 1873–8PubMedCrossRefGoogle Scholar
  7. 7.
    Muscatelli F, Abrous DN, Massacrier A, et al. Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum Mol Genet 2000; 9: 3101–10PubMedCrossRefGoogle Scholar
  8. 8.
    Bray GA, Dahms WT, Swerdloff RS, et al. The Prader-Willi syndrome: a study of 40 patients and a review of the literature. Medicine 1983; 62: 59–80PubMedCrossRefGoogle Scholar
  9. 9.
    Butler MG, Meaney FJ. Standards for selected anthropometric measurements in Prader-Willi syndrome. Pediatrics 1991; 88: 853–60PubMedGoogle Scholar
  10. 10.
    Wollmann HA, Schultz U, Grauer ML, et al. Reference values for height and weight in Prader-Willi syndrome based on 315 patients. Eur J Pediatr 1998; 157: 634–42PubMedCrossRefGoogle Scholar
  11. 11.
    Hauffa BP, Schlippe G, Roos M, et al. Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome. Acta Paediatr 2000; 89: 1302–11PubMedCrossRefGoogle Scholar
  12. 12.
    Brambilla P, Bosio L, Manzoni P, et al. Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr 1997; 65: 1369–74PubMedGoogle Scholar
  13. 13.
    Davies PSW, Joughlin C. Using stable isotopes to assess reduced physical activity of individuals with Prader-Willi syndrome. Am J Ment Retard 1993; 3: 349–53Google Scholar
  14. 14.
    Lee PD, Hwu K, Henson H, et al. Body composition studies in Prader-Willi syndrome: effects of growth hormone therapy. Basic Life Sci 1993; 60: 201–5PubMedGoogle Scholar
  15. 15.
    Boot AM, Bouquet J, de Ridder MAJ, et al. Determinants of body composition measured by dual-energy x-ray absorptiometry in Dutch children and adolescents. Am J Clin Nutr 1997; 66: 232–8PubMedGoogle Scholar
  16. 16.
    Ogle GD, Allen JR, Humphries IR, et al. Body composition assessment by dualenergy x-ray absorptiometry in subjects aged 4–26. Am J Clin Nutr 1995; 61: 746–53PubMedGoogle Scholar
  17. 17.
    Eiholzer U, l’Allemand D, Shlumpf M, et al. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediatr 2004; 144(6): 753–8PubMedGoogle Scholar
  18. 18.
    Davies PSW, Joughin C, Cole TJ, et al. Total energy expenditure in the Prader-Willi syndrome. Am J Clin Genet 1992; 44: 75–8CrossRefGoogle Scholar
  19. 19.
    Coplin SS, Hine J, Gormican A. Outpatient dietary management in the Prader-Willi syndrome. J Am Diet Assoc 1976; 68: 330–4PubMedGoogle Scholar
  20. 20.
    Nelson RA, Anderson LF, Gastineau CF, et al. Physiology and natural history of obesity. JAMA 1973; 223: 627–30PubMedCrossRefGoogle Scholar
  21. 21.
    van Mil EG, Westerterp KR, Rester AD, et al. Activity related energy expenditure in children and adolescents with Prader-Willi syndrome. Int J Obes Relat Metab Disord 2000; 24: 429–34CrossRefGoogle Scholar
  22. 22.
    van Mil EG, Westerterp KR, Gerver WJ, et al. Energy expenditure at rest and during sleep in children with Prader-Willi syndrome is explained by body composition. Am J Clin Nutr 2000; 71: 752–6Google Scholar
  23. 23.
    Schoeller DA, Levitsky LL, Bandibi LG, et al. Energy expenditure and body composition in Prader-Willi syndrome. Metabolism 1988; 37: 115–20PubMedCrossRefGoogle Scholar
  24. 24.
    Greenswag L. Adults with Prader-Willi syndrome: a survey of 232 cases. Dev Med Child Neurol 1987; 29: 145–52PubMedCrossRefGoogle Scholar
  25. 25.
    Laurance BM, Brito A, Wilkinson J. Prader-Willi syndrome after the age of 15 years. Arch Dis Child 1981; 56: 181–6PubMedCrossRefGoogle Scholar
  26. 26.
    Klish WJ. Childhood obesity: pathophysiology and treatment. Acta Paediatr Jpn 1995; 37: 1–5PubMedCrossRefGoogle Scholar
  27. 27.
    Rosengren A, Wedel H, Wilhelmsen L. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality: a prospective population study. Eur Heart J 1999; 20: 269–77PubMedCrossRefGoogle Scholar
  28. 28.
    Csabi G, Torok K, Jeges S, et al. Presence of metabolic cardiovascular syndrome in obese children. Eur J Pediatr 2000; 159: 91–4PubMedCrossRefGoogle Scholar
  29. 29.
    Karason K, Lindroos AK, Stenlof K, et al. Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study. Arch Intern Med 2000; 160: 1797–802PubMedCrossRefGoogle Scholar
  30. 30.
    Burman P, Ritzén EM, Lindgren AC. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 2001; 22(6): 787–99PubMedCrossRefGoogle Scholar
  31. 31.
    Höybye C, Hilding A, Jacobsson H, et al. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab 2002; 8: 3590–7CrossRefGoogle Scholar
  32. 32.
    Holm VA, Laurnen EL. Prader-Willi syndrome and scoliosis. Dev Med Child Neurol 1981; 23: 192–201PubMedCrossRefGoogle Scholar
  33. 33.
    Lee PDK. Endocrine and metabolic aspects of Prader-Willi syndrome. In: Greenswag LR, Alexander RC, editors. Management of Prader-Willi syndrome. New York: Springer-Verlag, 1995: 32–57CrossRefGoogle Scholar
  34. 34.
    Eiholzer U, Stutz K, Weinmann C, et al. Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr 1998; 157: 890–3PubMedCrossRefGoogle Scholar
  35. 35.
    Carrel AL, Myers SE, Whitman BY, et al. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J Pediatr 1999; 134: 215–21PubMedCrossRefGoogle Scholar
  36. 36.
    Fesseler WH, Bierich JR. Untersuchungen beim Prader-Labhart-Willi-syndrome. Monatsschr Kinderheilkd 1983; 131: 844–7PubMedGoogle Scholar
  37. 37.
    Costeff H, Holm VA, Ruvalcaba R, et al. Growth hormone secretion in Prader-Willi syndrome. Acta Paediatr Scand 1990; 79: 1059–62PubMedCrossRefGoogle Scholar
  38. 38.
    Calisti L, Giannessi N, Cesaretti G, et al. Studio endocrino nella sindrome di Prader-Willi: a proposito di 5 casi. Minerva Pediatr 1991; 43: 587–93PubMedGoogle Scholar
  39. 39.
    Huw K, Klish WJ, Henson H, et al. Endocrine status, growth hormone therapy and body composition in Prader-Willi syndrome [abstract no. 710]. Abstracts of the 74th Annual Meeting of the Endocrine Society; 1992 Jun 24–27; San Antonio (TX): 229Google Scholar
  40. 40.
    Cappa M, Grossi A, Borrelli P, et al. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhardt-Willi syndrome. Horm Res 1993; 39: 51–5PubMedCrossRefGoogle Scholar
  41. 41.
    Angulo M, Castro-Magana M, Mazur B, et al. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 1996; 3: 393–9Google Scholar
  42. 42.
    Grosso S, Cioni M, Buoni S, et al. Growth hormone secretion in Prader-Willi syndrome. J Endocrinol Invest 1998; 21: 418–22PubMedGoogle Scholar
  43. 43.
    Grugni G, Guzzaloni G, Moro D, et al. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostimine and administration in the Prader-Willi syndrome. Clin Endocrinol (Oxf) 1998; 48: 769–75CrossRefGoogle Scholar
  44. 44.
    Lindgren AC, Hagenäs L, Müller J, et al. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr 1998; 87: 28–31PubMedCrossRefGoogle Scholar
  45. 45.
    Sipilä I, Alanne S, Apajasalo M, et al. Growth hormone therapy in children with Prader-Willi syndrome: a preliminary report of one year treatment in 19 children [abstract]. Horm Res 1998; 50Suppl. 3: 1–150Google Scholar
  46. 46.
    Thacker MJ, Hainline B, St Dennis-Feezle L, et al. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm Res 1998; 49: 216–20PubMedCrossRefGoogle Scholar
  47. 47.
    Corrias A, Bellone J, Beccaria L, et al. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli: Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest 2000; 23: 84–9PubMedGoogle Scholar
  48. 48.
    Rosenbaum M, Gerner J, Leibel R. Effects of systemic (GH) administration on regional adipose tissue distribution in GH deficient children. J Clin Endocrinol Metab 1989; 69: 1274–81PubMedCrossRefGoogle Scholar
  49. 49.
    Lindgren AC, Hagenäs L, Müller J, et al. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. Acta Paediatr Suppl 1997; 423: 60–2PubMedCrossRefGoogle Scholar
  50. 50.
    Hauffa BP. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome. Acta Paediatr Suppl 1997; 423: 63–5PubMedCrossRefGoogle Scholar
  51. 51.
    Davies PSW, Evens S, Broomhead S, et al. Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome. Arch Dis Child 1998; 78: 474–6PubMedCrossRefGoogle Scholar
  52. 52.
    Eiholzer U, Gisin R, Weinmann C, et al. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr 1997; 157: 368–77CrossRefGoogle Scholar
  53. 53.
    Lindgren AC, Ritzén EM. Five years of growth hormone treatment in children with Prader-Willi syndrome. Acta Paediatr Suppl 1999; 433: 109–11CrossRefGoogle Scholar
  54. 54.
    Eiholzer U, l’Allemand D. Growth hormone normalizes height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. Horm Res 2000; 53: 185–92PubMedCrossRefGoogle Scholar
  55. 55.
    Lindgren AC. Long-term growth hormone therapy in children with Prader-Willi syndrome. Proceedings from 36th International Symposium: GH and Growth Factors in Endocrinology and Metabolism; 2004 May 14–15; GenevaGoogle Scholar
  56. 56.
    Myers SE, Carrel AL, Whitman BY, et al. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 2000; 137: 42–9PubMedCrossRefGoogle Scholar
  57. 57.
    Carrel AL, Myers SE, Whitman BY, et al. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002; 87(4): 1581–5PubMedCrossRefGoogle Scholar
  58. 58.
    Whitman BY, Myers S, Carrel A, et al. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year controlled study. Pediatrics 2002; 109(2): E35PubMedCrossRefGoogle Scholar
  59. 59.
    Carrel AL, Moerchen V, Myers SE, et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr 2004; 145: 744–9PubMedCrossRefGoogle Scholar
  60. 60.
    Arens R, Gozal D, Burrell BC, et al. Arousal and cardiorespiratory responses to hypoxia in Prader-Willi syndrome. Am J Respir Crit Care Med 1996; 153: 283–7PubMedGoogle Scholar
  61. 61.
    Schluter B, Buscbatz D, Trowitzsch E, et al. Respiratory control in children with Prader-Willi syndrome. Eur J Pediatr 1997; 156: 65–8PubMedCrossRefGoogle Scholar
  62. 62.
    Lindgren AC, Hellström LG, Ritzén EM, et al. Growth hormone treatment increases CO (2)-response, ventilation and central respiratory drive in children with Prader-Willi syndrome. Eur J Pediatr 1999; 158: 936–40PubMedCrossRefGoogle Scholar
  63. 63.
    Nixon GM, Brouillette RT. Sleep and breathing in Prader-Willi syndrome. Pediatr Pulmonol 2002; 34: 209–17PubMedCrossRefGoogle Scholar
  64. 64.
    Richards A, Quaghebeur G, Clift S, et al. The upper airway and sleep apnoea in the Prader-Willi syndrome. Clin Otolaryngol 1994; 19: 193–7PubMedCrossRefGoogle Scholar
  65. 65.
    Eiholzer U. Deaths in children with Prader-Willi syndrome. Horm Res 2005; 63: 33–9PubMedCrossRefGoogle Scholar
  66. 66.
    Haqq AM, Stadler DD, Jackson RH, et al. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88(5): 2206–12PubMedCrossRefGoogle Scholar
  67. 67.
    Lindgren AC, Hagenas L, Ritzen EM. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin hemostasis. Swedish National Growth Hormone Advisory Group. Horm Res 1999; 51: 157–61PubMedCrossRefGoogle Scholar
  68. 68.
    L’Allemand D, Eiholzer U, Schlumpf M, et al. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome. Horm Res 2003; 59(5): 239–48PubMedCrossRefGoogle Scholar
  69. 69.
    Zipf WB. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. Acta Paediatr Suppl 1999; 433: 115–7CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Pediatric Endocrinology Unit, Department of Woman and Child HealthAstrid Lindgren Children’s Hospital, Karolinska HospitalStockholmSweden

Personalised recommendations